Share This

PR Newswire Asia's news

 |   Detail   |   Print    Next page > 
     
Kerry Logistics Network Commended for Comprehensive Climate Disclosure at the HKQAA Hong Kong Green and Sustainability Contribution Awards 2024
2024-06-03T    Environmental Products & Services   Green Technology 
Darren Bishop Joins TradeFlow Capital Management as Head of Strategic Partnerships (UK/Europe)
2024-06-03T    Banking/Financial Service   Computer/Electronics 
Kerry Logistics Network Named Global Logistics Company of Excellence by Hong Kong Economic Journal Corporate Brand Awards of Excellence 2024
2024-06-03T    Computer/Electronics   Publishing/Information Service   Transportation 
Rokid AR Lite Crowdfunding Surpasses $600,000 with One Day Left for Early Bird Price of $479
2024-06-02T    Computer Hardware   Computer/Electronics   Entertainment 
Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
2024-06-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
2024-06-02T    Banking/Financial Service   Health Care/Hospital   Medical/Pharmaceuticals 
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
2024-06-02T    Health Care/Hospital   Medical/Pharmaceuticals 
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
2024-06-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
2024-06-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
2024-06-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.